Abstracts tagged "Patient reported outcomes"

Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: 2455 • ACR Convergence 2025
Lupus Intervention Fatigue Trial: Preliminary Analysis of Baseline Data
Justin Arnold¹, Linda Ehrlich-Jones², Dominique Kinnett-Hopkins³, Linda Van Horn⁴, Grace Whiteford⁴, Lutfiyya muhammad⁵, Jing Song⁶, Joan Chmiel⁷, Rowland Chang⁵, Pamela Semanik⁷, Anh Chung⁸, Daniel Erickson⁴, Christie Bartels⁹ and Rosalind Ramsey-Goldman⁵, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²Shirley Ryan AbilityLab, Aurora, IL, ³University of Michigan, Ypsilanti, MI, ⁴Feinberg School of Medicine, Chicago, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Worthington, MN, ⁷Feinberg School of Medicine, Chicago, IL, ⁸Northwestern University, Chicago, ⁹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with persistent fatigue. Physical activity (PA) & dietary intake are potential modifiable behaviors that can reduce fatigue in…
Abstract Number: 2063 • ACR Convergence 2025
Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation
Julie Paik¹, Andrea Young², Zuzana Bologna³, Will Kelly³, Chris Mecoli⁴, Jemima Albayda² and Lisa Christopher-Stine², ¹Johns Hopkins Rheumatology, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a chronic inflammatory myopathy characterized by muscle weakness and skin rashes, yet its full impact on patient-reported outcomes remains under-explored. We…
Abstract Number: 1425 • ACR Convergence 2025
Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
Pankti Mehta¹, Shangyi Gao², Virginia Carrizo Abarza³, Fadi Kharouf⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) significantly affects physical function (PF), which is influenced by both disease activity and structural damage. Despite its clinical importance, there is…
Abstract Number: 1251 • ACR Convergence 2025
Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.
Michelle Petri¹, Martha Stone², John Stone³, meredith Marinaro⁴, Matt Wilkinson⁵, Walter Lentfert⁶, Camille Kotton⁷, Jeffrey Gelfand⁸, Jane McDowell⁹ and Tricha Shivas¹⁰, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Steritas, LLC, Concord, MA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Novartis, Hartford, CT, ⁵UpThereEverywhere, London, United Kingdom, ⁶UpThereEverywhere, Charlotte, NC, ⁷Harvard Medical School, Boston, MA, ⁸UCSF Department of Neurology, Mill Valley, CA, ⁹Queens University Belfast, Belfast, United Kingdom, ¹⁰Foundation for Sarcoidosis Research, Chicago, IL
Background/Purpose: We report on two years of engagement with Sam, a patient-facing program to optimize the use of glucocorticoids and discontinue them when possible. We…
Abstract Number: 0523 • ACR Convergence 2025
SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
Jennifer Soung¹, Virginie Kelly², Marni Wiseman³, Adrian Rodriguez⁴, Theodore Alkousakis⁵, Olivia Choi⁵, Daphne Chan⁵, Katelyn Rowland⁵, Linda Hou⁶, Jenny Jeyarajah⁷, Nastaran Abbarin⁸, Elizabeth Skobelev⁵, Sancharitha Ramji⁵, James Krell⁹, Max Sauder¹⁰ and David Adam¹¹, ¹Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ²Saint-Louis Medical Clinic, Quebec, Canada, Quebec, Canada, ³SkinWise Dermatology, Manitoba, Canada, Manitoba, Canada, ⁴Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA, Nashville, TN, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, ⁷Johnson & Johnson, Horsham, PA, USA, Horsham, ⁸Janssen Inc, Toronto, ON, Canada, Toronto, Canada, ⁹Total Skin & Beauty Dermatology Center, Birmingham, AL, USA, Birmingham, ¹⁰Probity Medical Research, ON, Canada; University of Toronto, ON, Canada, Toronto, Canada, ¹¹CCA Medical Research, ON, Canada, Toronto, Canada
Background/Purpose: Even low body surface area (BSA) psoriasis can be extremely bothersome to patients and can have a significant impact on their lives just as…
Abstract Number: 0372 • ACR Convergence 2025
Development and Implementation of a Remote Educational Program to Optimize Safe Medication Use in Older Veterans with Rheumatic Diseases
Maria Romero Noboa¹, Hannah Howell², Angelo Gaffo³ and Maria I. ("Maio") Danila⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Symptomatic treatment in rheumatic and musculoskeletal diseases (RMDs) – including glucocorticoids (GCs) and non-steroidal anti-inflammatory drugs (NSAIDs) – can result in improved quality of…
Abstract Number: 2441 • ACR Convergence 2025
Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Zahi Touma¹, Cynthia Aranow², Ioannis Parodis³, Rosalind Ramsey-Goldman⁴, Matthias Schneider⁵, Christine de La Loge⁶, Teri Jimenez⁷, Mina Nejati⁸ and Laurent arnaud⁹, ¹University of Toronto, Toronto, ON, Canada, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁶UCB, Brussels, Belgium, ⁷UCB, Raleigh, NC, ⁸Biogen, Cambridge, MA, ⁹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: SLE imposes significant disease burden and diminishes health-related quality of life (HRQoL); improvement of HRQoL is therefore a key treatment goal in SLE.1,2 Dapirolizumab…
Abstract Number: 1969 • ACR Convergence 2025
Enhancing Objective Evaluation of Raynaud’s in Veterans with Scleroderma-related Hand Pain: Integrating Patient Reported Outcomes and Nailfold Capillaroscopy
Genessis Maldonado¹, Sowmika Rao¹ and Tracy Frech², ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Raynaud’s phenomenon (RP) is a painful and disabling feature of systemic sclerosis (SSc) that significantly impairs quality of life. Tools that integrate subjective symptom…
Abstract Number: 1410 • ACR Convergence 2025
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Connor Vershel¹, Mark Hwang², John Reveille³, Seokhun Kim⁴, Matthew A. Brown⁵, Michael Weisman⁶, Mariko Ishimori⁶ and Michael Ward⁷, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX, ²UTHealth Houston, Houston, TX, ³Department of Medicine, University of Texas Medical Center, Houston, TX, ⁴UTHealth Houston, Houston, ⁵Genomics England, London, United Kingdom, ⁶Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD
Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the…
Abstract Number: 1216 • ACR Convergence 2025
Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies
Sung-Ki Lee¹, Kristin Wipfler², Ethan Ritz³, Burcu Aydemir⁴, Kaleb Michaud⁵ and Didem Saygin⁶, ¹Rush Medical College, Chicago, IL, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune disorders characterized by chronic skeletal muscle inflammation leading to muscle weakness and limitations in physical…
Abstract Number: 0520 • ACR Convergence 2025
Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
Stephanie Lee¹, Chadwick Johr², Nora Sandorfi², Ali Dhanaliwala² and Dana DiRenzo², ¹University of Pennsylvania & Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Salivary Gland Ultrasound (SGUS) can be useful in the evaluation and management of Sjögren’s Disease (SjD) but its use has been limited to trained…
Abstract Number: 0368 • ACR Convergence 2025
Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine
Hareem Farooq¹, Lesley Jackson¹, Rahima Begum², Gary Cutter², Kenneth Saag³, Jinoos Yazdany⁴ and Maria I. ("Maio") Danila⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴UCSF, San Francisco, CA, ⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Home-based telemedicine is an efficient healthcare delivery approach. A recent randomized clinical trial (RCT) found that in-person visits may be preferred among rheumatology patients.…
Abstract Number: 2435 • ACR Convergence 2025
Relevant Symptoms and Signs of Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Among Participants in a Phase 2 Clinical Trial: Patient-Embedded Qualitative Interviews
Victoria Werth¹, Coburn Hobar², Rachana Agrawal³, Miriam Kimel⁴, Mona L. Martin⁴, Julia R. Correll⁴, Jiyoon Choi², Antonia Christodoulou⁵, Laurie Eliason⁶ and Joseph F Merola⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Princeton, ⁴Evidera, Wilmington, NC, ⁵BMS, Princeton, NJ, ⁶Bristol Myers Squibb,, Princeton, NJ, ⁷Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Deucravacitinib is an oral, selective, allosteric TYK2 inhibitor currently under investigation for the treatment of active discoid and/or subacute cutaneous lupus erythematosus (DLE and…
Abstract Number: 1961 • ACR Convergence 2025
Clinical Utility and Patient Experience of Ultrasound-Guided Synovial Biopsy in Refractory Arthritis: A Case Series from a Secondary Care Center
Maria Beatriz Paredes Romero¹, Elisabet Castañeda Estévez², Martina Steiner³, Marco Algarra- San José³, Ana Valeria Acosta³, Tatiana Cobo-Ibáñez⁴, Isabel De la Cámara³, Ana Victoria Esteban Vázquez⁵, Patricia Richi³, Maria Liz Romero-Bogado³, Laura Trives⁵, Cristina Vergara-Dangond⁴, Jorge palomar-Ramos³ and Santiago Muñoz⁵, ¹Infanta Sofía University Hospital, Madrid, Spain, ²Hospital Universitario Infanta Sofía, Madrid, Spain, ³Infanta Sofía University Hospital, Madrid, Spain, ⁴Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de Los Reyes, Madrid, Spain, ⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain
Background/Purpose: Diagnosing arthritis remains challenging in a subset of patients despite advances in imaging, serological markers, and clinical scoring systems. Ultrasound-guided synovial biopsy (USG-SB) stands…

1
2
3
…
50
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].